Please assess the completion status of the following clinical trial:

Trial Title: Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Informed consent~* Otherwise healthy outpatient with mountain cedar allergy~* Male or eligible female Females of childbearing potential must commit to the consistent and correct use of an acceptable method of birth control~* Age 12 years or older at Visit 2~* Diagnosis of seasonal allergic rhinitis (SAR) to mountain cedar~* Adequate exposure to mountain cedar pollen~* Ability to comply with study procedures~* Literate~Exclusion criteria:~* Significant concomitant medical conditions~* Use of intranasal corticosteroids within four weeks prior to Visit 1; use of inhaled, oral, intramuscular, intravenous, ocular, and/or dermatological corticosteroid (with the exception of hydrocortisone cream/ointment, 1% or less) within eight weeks prior to Visit 1.~* Use of other allergy medications within specific timeframes relative to Visit 1~* Use of other medications that may affect allergic rhinitis or its symptoms~* Use of immunosuppressive medications eight weeks prior to screening and during the study~* Immunotherapy patients who are not stable on current dose~* Use of any medications that significantly alters the pharmacokinetics of fluticasone furoate or fexofenadine~* Allergy/Intolerance to corticosteroids, antihistamines, or any excipients in the two products~* Use of contact lenses~* Recent clinical trial/experimental medication experience within 30 days of Visit 1~* Subject previously failed the 21-day screen period or failed to complete the treatment period~* Positive or inconclusive pregnancy test or female who is breastfeeding~* Employee or relative affiliation with investigational site~* Current tobacco use~* Active chickenpox or measles or exposure in the last 3 weeks

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).